In re Akari Therapeutics PLC Securities Litigation, No. 17-cv-3577 (KPF)

The Rosen Law Firm was sole Lead Counsel in this class action in the U.S. District Court for the Southern District of New York. The complaint alleged violations of §§10b and 20(a) of the Securities Exchange Act arising out of the Company’s issuance of materially false and misleading statements about the results of a clinical study. The parties settled this case for $2.7 million in cash.

Scroll to Top